Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

Gene

Search results

No.

KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related

Long-term potentiation 💬

[1] BRAF 💬

Dabrafenib 💬

Dabrafenib

[1] 34 💬

Long-term potentiation 💬

[1] BRAF 💬

Dabrafenib mesylate 💬

Dabrafenib

[1] 34 💬

Long-term potentiation 💬

[2] BRAF, RAF1 💬

Sorafenib tosylate 💬

Sorafenib

[2] 34, 86 💬

Long-term potentiation 💬

[2] BRAF, RAF1 💬

Sorafenib 💬

Sorafenib

[2] 34, 86 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Amlodipine besylate 💬

Amlodipine

[3] 51, 67, 298 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
67	Polycystic kidney disease;PKD;PCKD;Polycystic kidney;Autosomal dominant PKD;ADPKD;Autosomal recessive PKD;ARPKD;
298	Hereditary pancreatitis;Chronic pancreatitis;

Long-term potentiation 💬

[1] CACNA1C 💬

Amlodipine maleate 💬

Amlodipine

[3] 51, 67, 298 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
67	Polycystic kidney disease;PKD;PCKD;Polycystic kidney;Autosomal dominant PKD;ADPKD;Autosomal recessive PKD;ARPKD;
298	Hereditary pancreatitis;Chronic pancreatitis;

Long-term potentiation 💬

[1] CACNA1C 💬

Amlodipine 💬

Amlodipine

[3] 51, 67, 298 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
67	Polycystic kidney disease;PKD;PCKD;Polycystic kidney;Autosomal dominant PKD;ADPKD;Autosomal recessive PKD;ARPKD;
298	Hereditary pancreatitis;Chronic pancreatitis;

Long-term potentiation 💬

[1] CACNA1C 💬

Amlodipine benzoate 💬

Amlodipine

[3] 51, 67, 298 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
67	Polycystic kidney disease;PKD;PCKD;Polycystic kidney;Autosomal dominant PKD;ADPKD;Autosomal recessive PKD;ARPKD;
298	Hereditary pancreatitis;Chronic pancreatitis;

Long-term potentiation 💬

[1] CACNA1C 💬

Bevantolol hydrochloride 💬

Bevantolol

[1] 8 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Cilnidipine 💬

Cilnidipine

[1] 67 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Diltiazem hydrochloride 💬

Name	Other Names
Diltiazem hydrochloride	Diltiazem hydrochloride (JP18/USP) Cardizem (TN) Cartia XT (TN) Dilacor XR (TN) Dilt-CD (TN) CARDIZEM CARDIZEM CD CARDIZEM LA DILTIAZEM HCL CD DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE TIAZAC CARTIA CARTIA XT DILTIAZEM HCI DILTIAZEM HCL ER DILTIAZEM HYDROCHLORIDE DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE MATZIM LA TIADYLT ER

Diltiazem

[4] 51, 58, 86, 88 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
58	Hypertrophic cardiomyopathy;HCM;
86	Pulmonary arterial hypertension;PAH;
88	Chronic thromboembolic pulmonary hypertension;CTEPH;Idiopathic chronic pulmonary thromboembolism;

Long-term potentiation 💬

[1] CACNA1C 💬

Diltiazem malate 💬

Diltiazem

[4] 51, 58, 86, 88 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
58	Hypertrophic cardiomyopathy;HCM;
86	Pulmonary arterial hypertension;PAH;
88	Chronic thromboembolic pulmonary hypertension;CTEPH;Idiopathic chronic pulmonary thromboembolism;

Long-term potentiation 💬

[1] CACNA1C 💬

Diltiazem 💬

Diltiazem

[4] 51, 58, 86, 88 💬

Disease ID	Name
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
58	Hypertrophic cardiomyopathy;HCM;
86	Pulmonary arterial hypertension;PAH;
88	Chronic thromboembolic pulmonary hypertension;CTEPH;Idiopathic chronic pulmonary thromboembolism;

Long-term potentiation 💬

[1] CACNA1C 💬

Isradipine 💬

Isradipine

[1] 6 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Nicardipine hydrochloride 💬

Nicardipine

[2] 70, 86 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Nicardipine 💬

Nicardipine

[2] 70, 86 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Nifedipine 💬

Nifedipine

[1] 81 💬

Disease ID	Name
81	Congenital adrenal hyperplasia;CAH;Congenital adrenal enzyme deficiency;Congenial adrenal cortex enzyme deficiency;Congenital Lipoid Adrenal Hyperplasia;3β-Hydroxysteroid Dehydrogenase Deficiency;21-Hydroxylase deficiency;21-OHD;11β-Hydroxylase deficiency;17α-Hydroxylase deficiency;P450 oxidoreductase deficiency;

Long-term potentiation 💬

[1] CACNA1C 💬

Nilvadipine 💬

Nilvadipine

[1] 90 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Perhexiline maleate 💬

Perhexiline

[2] 58, 272 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Perhexiline 💬

Perhexiline

[2] 58, 272 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Propiverine hydrochloride 💬

Propiverine

[1] 226 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Propiverine 💬

Propiverine

[1] 226 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Verapamil hydrochloride 💬

Verapamil

[4] 58, 96, 140, 167 💬

Long-term potentiation 💬

[1] CACNA1C 💬

Verapamil 💬

Verapamil

[4] 58, 96, 140, 167 💬

Long-term potentiation 💬

[3] CACNA1C, GRIA1, GRIA2 💬

Topiramate 💬

Topiramate

[5] 6 , 140, 144, 156, 193 💬

Long-term potentiation 💬

[2] GRIA1, GRIA2 💬

Perampanel 💬

Perampanel

[3] 2 , 6 , 144 💬

Long-term potentiation 💬

[2] GRIA1, GRIA2 💬

Perampanel hydrate 💬

Perampanel

[3] 2 , 6 , 144 💬

Long-term potentiation 💬

[2] GRIA1, GRIA2 💬

Talampanel 💬

Talampanel

[2] 2 , 6 💬

Long-term potentiation 💬

[7] GRIA1, GRIA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIA1	glutamate ionotropic receptor AMPA type subunit 1
GRIA2	glutamate ionotropic receptor AMPA type subunit 2
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Riluzole 💬

Riluzole

[8] 2 , 3 , 5 , 8 , 13, 17, 203, 206 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
3	Spinal muscular atrophy;SMA;Myelopathic muscular atrophy;Werdnig-Hoffman disease;Dubowitz disease;Kugelberg-Welander disease;
5	Progressive supranuclear palsy;PSP;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
17	Multiple system atrophy;MSA;MSA;Olivopontocerebellar atrophy;OPCA;Striatonigral degeneration;Shy-Drager syndrome;
203	22q11.2 deletion syndrome;
206	Fragile X syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Acamprosate calcium 💬

Acamprosate

[2] 6 , 206 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Acamprosate 💬

Acamprosate

[2] 6 , 206 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Amantadine hydrochloride 💬

Amantadine

[5] 2 , 6 , 8 , 13, 127 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
127	Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Amantadine 💬

Amantadine

[5] 2 , 6 , 8 , 13, 127 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
127	Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Dextromethorphan hydrobromide 💬

Dextromethorphan

[10] 2 , 6 , 8 , 13, 21, 46, 85, 96, 97, 156 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
21	Mitochondrial disease;Choronic progressive external ophthalmolegia;CPEO;Leigh syndrome;Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episode;MELAS;Myoclonus epilepsy associated with ragged-red fibers;MERRF;Mitochondrial respiratory chain disorders;Pearson syndrome;
46	Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV;
85	Idiopathic interstitial pneumonia;IIPs;Idiopathic pulmonary fibrosis;IPF;Idiopathic non-specific interstitial pneumonia;Idiopathic NSIP;Respiratory bronchiolitis - associated interstitial lung disease;RB-ILD;Desquamative interstitial pneumonia;DIP;Cryptogenic organizing pneumonia;COP;Acute interstitial pneumonia;AIP;Idiopathic lymphocytic interstitial pneumonia;Idiopathic LIP;Idiopathic PPFE;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
156	Rett syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Dextromethorphan 💬

Dextromethorphan

[10] 2 , 6 , 8 , 13, 21, 46, 85, 96, 97, 156 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
21	Mitochondrial disease;Choronic progressive external ophthalmolegia;CPEO;Leigh syndrome;Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episode;MELAS;Myoclonus epilepsy associated with ragged-red fibers;MERRF;Mitochondrial respiratory chain disorders;Pearson syndrome;
46	Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV;
85	Idiopathic interstitial pneumonia;IIPs;Idiopathic pulmonary fibrosis;IPF;Idiopathic non-specific interstitial pneumonia;Idiopathic NSIP;Respiratory bronchiolitis - associated interstitial lung disease;RB-ILD;Desquamative interstitial pneumonia;DIP;Cryptogenic organizing pneumonia;COP;Acute interstitial pneumonia;AIP;Idiopathic lymphocytic interstitial pneumonia;Idiopathic LIP;Idiopathic PPFE;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
156	Rett syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Esketamine 💬

Esketamine

[7] 2 , 4 , 6 , 70, 96, 97, 156 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
4	Primary lateral sclerosis;PLS;
6	Parkinson disease;Disease Parkinson's;
70	Spinal stenosis;Extensive spinal canal stenosis;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
156	Rett syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Esketamine hydrochloride 💬

Esketamine

[7] 2 , 4 , 6 , 70, 96, 97, 156 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
4	Primary lateral sclerosis;PLS;
6	Parkinson disease;Disease Parkinson's;
70	Spinal stenosis;Extensive spinal canal stenosis;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
156	Rett syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Ketamine hydrochloride 💬

Ketamine

[6] 6 , 13, 70, 113, 156, 215 💬

Disease ID	Name
6	Parkinson disease;Disease Parkinson's;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
70	Spinal stenosis;Extensive spinal canal stenosis;
113	Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy;
156	Rett syndrome;
215	Tetralogy of Fallot;Fallot tetralogy;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Ketamine 💬

Ketamine

[6] 6 , 13, 70, 113, 156, 215 💬

Disease ID	Name
6	Parkinson disease;Disease Parkinson's;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
70	Spinal stenosis;Extensive spinal canal stenosis;
113	Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy;
156	Rett syndrome;
215	Tetralogy of Fallot;Fallot tetralogy;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Latrepirdine 💬

Latrepirdine

[1] 8 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Latrepirdine dihydrochloride 💬

Latrepirdine

[1] 8 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Memantine hydrochloride 💬

Memantine

[8] 2 , 6 , 8 , 13, 49, 127, 205, 206 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
49	Systemic lupus erythematosus;SLE;
127	Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia;
205	Fragile X syndrome related disease;Fragile X-associated tremor/ataxia syndrome;FXTAS;Fragile X-associated tremor;Ataxia syndrome;
206	Fragile X syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Memantine 💬

Memantine

[8] 2 , 6 , 8 , 13, 49, 127, 205, 206 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
8	Huntington disease;Huntington chorea;
13	Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis;
49	Systemic lupus erythematosus;SLE;
127	Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia;
205	Fragile X syndrome related disease;Fragile X-associated tremor/ataxia syndrome;FXTAS;Fragile X-associated tremor;Ataxia syndrome;
206	Fragile X syndrome;

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Methadone hydrochloride 💬

Methadone

[1] 60 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Methadone 💬

Methadone

[1] 60 💬

Long-term potentiation 💬

[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬

Name	Full Name
GRIN1	glutamate ionotropic receptor NMDA type subunit 1
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D

Tenocyclidine 💬

Tenocyclidine

[1] 36 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Binimetinib 💬

Binimetinib

[1] 34 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Cobimetinib 💬

Cobimetinib

[1] 280 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Cobimetinib fumarate 💬

Cobimetinib

[1] 280 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Mirdametinib 💬

Mirdametinib

[4] 34, 278, 279, 280 💬

Disease ID	Name
34	Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2;
278	Huge lymphatic malformation with cervicofacial lesion;Huge lymphatic malformation;Lymphatic malformation;
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion;Huge venous malformation;Venous malformation;Gigantic venous malformation;
280	Huge arteriovenous malformation with cervicofacial or limb lesion;Huge arteriovenous malformation;Arteriovenous malformation;Gigantic arteriovenous malformation;

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Selumetinib 💬

Selumetinib

[1] 34 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Selumetinib sulfate 💬

Selumetinib

[1] 34 💬

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Trametinib 💬

Trametinib

[6] 2 , 34, 58, 195, 279, 280 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
34	Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2;
58	Hypertrophic cardiomyopathy;HCM;
195	Noonan syndrome;
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion;Huge venous malformation;Venous malformation;Gigantic venous malformation;
280	Huge arteriovenous malformation with cervicofacial or limb lesion;Huge arteriovenous malformation;Arteriovenous malformation;Gigantic arteriovenous malformation;

Long-term potentiation 💬

[2] MAP2K1, MAP2K2 💬

Trametinib dimethyl sulfoxide 💬

Trametinib

[6] 2 , 34, 58, 195, 279, 280 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
34	Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2;
58	Hypertrophic cardiomyopathy;HCM;
195	Noonan syndrome;
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion;Huge venous malformation;Venous malformation;Gigantic venous malformation;
280	Huge arteriovenous malformation with cervicofacial or limb lesion;Huge arteriovenous malformation;Arteriovenous malformation;Gigantic arteriovenous malformation;

Long-term potentiation 💬

[5] PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬

Pimecrolimus 💬

Pimecrolimus

[1] 160 💬

Disease ID

Name

160

Congenital ichthyosis;Keratinopathic ichthyosis;Epidermolytic ichthyosis;Superficial epidermolytic ichthyosis;Harlequin ichthyosis;Autosomal recessive congenital ichthyosis;Congenital Ichthyosiform Erythroderma;Foliate ichthyosis;Ichthyosis syndrome;Netherton syndrome;Sjogren-Larsson syndrome;Sjögren-Larsson syndrome;Keratitis-ichtyosis-deafness syndrome;KID syndrome;Dorfman-Chanarin syndrome;Neutral lipid storage disease;NLSD;Multiple sulfatase deficiency;Austin disease;Recessive X-linked ichthyosis;RXLI;X-linked recessive ichthyosis;Ichthyosis, brittle hair, impaired intelligence, decreased fertility and short stature;IBID;Trichothiodystrophy;Follicular ichthyosis;Congenital hemidysplasia, ichthyosiform erythroderma or nevus, and limb defects syndrome;CHILD syndrome;Conradi-Hunermann-Happle syndrome;Conradi-Hünermann-Happle syndrome;CHHS;

Long-term potentiation 💬

[5] PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬

Tacrolimus 💬

Tacrolimus

[33] 2 , 6 , 11, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 234, 283, 284, 285, 286, 299 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
11	Myasthenia gravis;MG;
36	Epidermolysis bullosa;Kindler syndrome;
46	Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV;
49	Systemic lupus erythematosus;SLE;
50	Dermatomyositis;Polymyositis;
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
53	Sjogren syndrome;Sjögren syndrome;Syndrome Sjogren's;Autoimmune exocrinopathy;
56	Behcet disease;Behçet disease;BD;
60	Aplastic anemia;
61	Autoimmune hemolytic anemia;AIHA;Cold agglutinin disease;CAD;Paroxysmal cold hemoglobinuria;Evans syndrome;
62	Paroxysmal nocturnal hemoglobinuria;PNH;
65	Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3;
66	IgA nephropathy;IgA nephritis;Berger disease;IgA-IgG nephropathy;
95	Autoimmune hepatitis;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
113	Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy;
151	Rasmussen encephalitis;
158	Tuberous sclerosis;Tuberous sclerosis complex;TSC;
164	Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome;
222	Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN;
224	Purpura nephritis;Henoch-Schönlein purpura nephritis;HSPN;
226	Interstitial cystitis with Hunners ulcer;Interstitial cystitis;
227	Osler disease;Hereditary hemorrhagic telangiectasia;HHT;Osler-Weber-Rendu disease;
228	Bronchiolitis obliterans;Obliterating bronchiolitis;
234	Peroxisomal disease (except Adrenoleukodystrophy);Peroxisomal disease;Peroxisomal disorder;Peroxisome biogenesis disorder;Contiguous ABCD1/DXS1357E deletion syndrome;CADDS;Peroxisome biogenesis disorder;PBD;PEX gene disorder;Zellweger syndrome;Neonatal adrenoleukodystrophy;Infantile Refsum disease;Rhizomelic chondrodysplasia punctata type 1;RCDP type 1;RCDP1;Peroxisomal beta-oxidation enzyme deficiency;Acyl-CoA oxidase deficiency;AOX deficiency;D-Bifunctional protein deficiency;DBP deficiency;Sterol carrier protein X deficiency;SCPx deficiency;2-methylacyl-CoA racemase deficiency;Alpha-methylacyl-CoA racemase deficiency;AMACR deficiency;Plasmalogen biosynthesis enzyme deficiency;Rhizomelic chondrodysplasia punctata type 2;RCDP type 2;RCDP2;Rhizomelic chondrodysplasia punctata type 3;RCDP type 3;RCDP3;Refsum disease;Primary hyperoxaluria type 1;PH1;Primary hyperoxaluria;Acatalasemia;Acatalasia;Takahara disease;
283	Acquired pure red cell aplasia;Pure red cell aplasia;
284	Diamond-Blackfan anemia;
285	Fanconi anemia;
286	Hereditary sideroblastic anemia;Congenital sideroblastic anemia;Sideroblastic anemia;
299	Cystic fibrosis;CF;

Long-term potentiation 💬

[5] PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬

Voclosporin 💬

Voclosporin

[2] 49, 222 💬

Disease ID	Name
49	Systemic lupus erythematosus;SLE;
222	Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN;

Long-term potentiation 💬

[5] PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬

Tacrolimus 💬

Tacrolimus

[33] 2 , 6 , 11, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 234, 283, 284, 285, 286, 299 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis;ALS;
6	Parkinson disease;Disease Parkinson's;
11	Myasthenia gravis;MG;
36	Epidermolysis bullosa;Kindler syndrome;
46	Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV;
49	Systemic lupus erythematosus;SLE;
50	Dermatomyositis;Polymyositis;
51	Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc;
53	Sjogren syndrome;Sjögren syndrome;Syndrome Sjogren's;Autoimmune exocrinopathy;
56	Behcet disease;Behçet disease;BD;
60	Aplastic anemia;
61	Autoimmune hemolytic anemia;AIHA;Cold agglutinin disease;CAD;Paroxysmal cold hemoglobinuria;Evans syndrome;
62	Paroxysmal nocturnal hemoglobinuria;PNH;
65	Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3;
66	IgA nephropathy;IgA nephritis;Berger disease;IgA-IgG nephropathy;
95	Autoimmune hepatitis;
96	Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
113	Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy;
151	Rasmussen encephalitis;
158	Tuberous sclerosis;Tuberous sclerosis complex;TSC;
164	Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome;
222	Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN;
224	Purpura nephritis;Henoch-Schönlein purpura nephritis;HSPN;
226	Interstitial cystitis with Hunners ulcer;Interstitial cystitis;
227	Osler disease;Hereditary hemorrhagic telangiectasia;HHT;Osler-Weber-Rendu disease;
228	Bronchiolitis obliterans;Obliterating bronchiolitis;
234	Peroxisomal disease (except Adrenoleukodystrophy);Peroxisomal disease;Peroxisomal disorder;Peroxisome biogenesis disorder;Contiguous ABCD1/DXS1357E deletion syndrome;CADDS;Peroxisome biogenesis disorder;PBD;PEX gene disorder;Zellweger syndrome;Neonatal adrenoleukodystrophy;Infantile Refsum disease;Rhizomelic chondrodysplasia punctata type 1;RCDP type 1;RCDP1;Peroxisomal beta-oxidation enzyme deficiency;Acyl-CoA oxidase deficiency;AOX deficiency;D-Bifunctional protein deficiency;DBP deficiency;Sterol carrier protein X deficiency;SCPx deficiency;2-methylacyl-CoA racemase deficiency;Alpha-methylacyl-CoA racemase deficiency;AMACR deficiency;Plasmalogen biosynthesis enzyme deficiency;Rhizomelic chondrodysplasia punctata type 2;RCDP type 2;RCDP2;Rhizomelic chondrodysplasia punctata type 3;RCDP type 3;RCDP3;Refsum disease;Primary hyperoxaluria type 1;PH1;Primary hyperoxaluria;Acatalasemia;Acatalasia;Takahara disease;
283	Acquired pure red cell aplasia;Pure red cell aplasia;
284	Diamond-Blackfan anemia;
285	Fanconi anemia;
286	Hereditary sideroblastic anemia;Congenital sideroblastic anemia;Sideroblastic anemia;
299	Cystic fibrosis;CF;

Long-term potentiation 💬

[5] PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬

Cyclosporine 💬

Name	Other Names
Cyclosporine	Cyclosporine (USP) Ciclosporin (JP18) Gengraf (TN) Neoral (TN) Restasis (TN) Sandimmune (TN) CEQUA NEORAL RESTASIS RESTASIS MULTIDOSE SANDIMMUNE VERKAZIA VEVYE CYCLOSPORINE CYCLOSPORINE, MODFIED GENGRAF

Cyclosporine

[42] 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬

Disease ID	Name
11	Myasthenia gravis;MG;
19	Lysosomal storage disease;Lysosomal disease;Gaucher disease;Niemann-Pick disease type A/B;Niemann-Pick type A;NPD-A;NPA;Niemann-Pick type B;NPD-B;NPB;Acid sphingomyelinase deficiency;ASMD;Niemann-Pick disease type C;Niemann-Pick type C;NPD-C;NPC;GM1-gangliosidosis;GM1-gangliosidoses;GM2-gangliosidosis;GM2-gangliosidoses;Tay-Sachs disease;Sandhoff disease;Krabbe disease;Metachromatic leukodystrophy;MLD;Multiple-sulfatase deficiency;Farber disease;Mucopolysaccharidosis type I;Mucopolysaccharidosis I;MPS I;Hurler syndrome;Hurler-Scheie syndrome;Scheie syndrome;Mucopolysaccharidosis type II;Mucopolysaccharidosis II;MPS II;Hunter syndrome;Mucopolysaccharidosis type III;Mucopolysaccharidosis III;MPS III;Sanfilippo syndrome;Mucopolysaccharidosis type IV;Mucopolysaccharidosis IV;MPS IV;MPS IVA;Morquio syndrome;Morquio A syndrome;Mucopolysaccharidosis type VI;Mucopolysaccharidosis VI;MPS VI;Maroteaux-Lamy syndrome;Mucopolysaccharidosis type VII;Mucopolysaccharidosis VII;MPS VII;Sly syndrome;Mucopolysaccharidosis type IX;Mucopolysaccharidosis IX;MPS IX;Hyaluronidase deficiency;Sialidosis;Galactosialidosis;Mucolipidosis II;Mucolipidosis type II;I-cell disease;Mucolipidosis III;Mucolipidosis type III;Alpha-Mannosidosis;Alpha-Mannosidase Deficiency;Beta-Mannosidosis;Beta-Mannosidase Deficiency;Fucosidosis;Aspartylglucosaminuria;Schindler disease;Kanzaki disease;Pompe disease;Acid lipase deficiency;Wolman disease;Cholesterol ester storage disease;Danon disease;Free sialic acid storage disease;Infantile sialic acid storage disease;ISSD;Salla disease;Ceroid lipofuscinosis;Fabry disease;Cystinosis;
20	Adrenoleukodystrophy;ALD;Childhood cerebral ALD;CCALD;Adolescent cerebral ALD;AdoCALD;AdolCALD;Adrenomyeloneuropathy;AMN;Adult cerebral ALD;ACALD;
26	HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM;
28	Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis;
36	Epidermolysis bullosa;Kindler syndrome;
40	Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome;
41	Giant cell arteritis;Temporal arteritis;
42	Polyarteritis nodosa;PAN;
45	Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS;
46	Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV;
49	Systemic lupus erythematosus;SLE;
50	Dermatomyositis;Polymyositis;
53	Sjogren syndrome;Sjögren syndrome;Syndrome Sjogren's;Autoimmune exocrinopathy;
54	Adult still disease;Adult-onset Still's disease;
55	Relapsing polychondritis;
56	Behcet disease;Behçet disease;BD;
58	Hypertrophic cardiomyopathy;HCM;
60	Aplastic anemia;
61	Autoimmune hemolytic anemia;AIHA;Cold agglutinin disease;CAD;Paroxysmal cold hemoglobinuria;Evans syndrome;
62	Paroxysmal nocturnal hemoglobinuria;PNH;
63	Idiopathic thrombocytopenic purpura;Primary immune thrombocytopenia;Immune thrombocytopenic purpura;
64	Thrombotic thrombocytopenic purpura;TTP;Upshaw-Schulman syndrome;USS;
65	Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3;
93	Primary biliary cholangitis;Primary biliary cirrhosis;PBC;
95	Autoimmune hepatitis;
97	Ulcerative colitis;UC;Inflammatory bowel disease;IBD;
107	Juvenile idiopathic arthritis;JIA;Systemic juvenile idiopathic arthritis;Systemic-onset juvenile idiopathic arthritis;sJIA;Joint-type juvenile idiopathic arthritis;Joint-type juvenile idiopathic arthritis;Joint-type JIA;
113	Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy;
162	Pemphigoid;
164	Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome;
222	Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN;
226	Interstitial cystitis with Hunners ulcer;Interstitial cystitis;
228	Bronchiolitis obliterans;Obliterating bronchiolitis;
234	Peroxisomal disease (except Adrenoleukodystrophy);Peroxisomal disease;Peroxisomal disorder;Peroxisome biogenesis disorder;Contiguous ABCD1/DXS1357E deletion syndrome;CADDS;Peroxisome biogenesis disorder;PBD;PEX gene disorder;Zellweger syndrome;Neonatal adrenoleukodystrophy;Infantile Refsum disease;Rhizomelic chondrodysplasia punctata type 1;RCDP type 1;RCDP1;Peroxisomal beta-oxidation enzyme deficiency;Acyl-CoA oxidase deficiency;AOX deficiency;D-Bifunctional protein deficiency;DBP deficiency;Sterol carrier protein X deficiency;SCPx deficiency;2-methylacyl-CoA racemase deficiency;Alpha-methylacyl-CoA racemase deficiency;AMACR deficiency;Plasmalogen biosynthesis enzyme deficiency;Rhizomelic chondrodysplasia punctata type 2;RCDP type 2;RCDP2;Rhizomelic chondrodysplasia punctata type 3;RCDP type 3;RCDP3;Refsum disease;Primary hyperoxaluria type 1;PH1;Primary hyperoxaluria;Acatalasemia;Acatalasia;Takahara disease;
269	Pyogenic arthritis;Pyoderma gangrenosum;Acne syndrome;PAPA syndrome;
274	Osteogenesis Imperfecta;
283	Acquired pure red cell aplasia;Pure red cell aplasia;
284	Diamond-Blackfan anemia;
285	Fanconi anemia;
302	Leber hereditary optic neuropathy;LHON;Leber disease;
326	Osteopetrosis;Neonatal/infantile osteopetrosis;Intermediate osteopetrosis;Delayed-onset osteopetrosis;

Long-term potentiation 💬

[1] PRKCB 💬

Enzastaurin hydrochloride 💬

Enzastaurin

[1] 168 💬

Disease ID

Name

168

Ehlers-Danlos syndrome;EDS;Classic EDS;Classical EDS;cEDS;Classical-like Ehlers-Danlos syndrome;Classical-like EDS;clEDS;Cardiac-valvular Ehlers-Danlos syndrome;cvEDS;Vascular Ehlers-Danlos syndrome;Vascular EDS;vEDS;Hypermobile Ehlers-Danlos syndrome;Hypermobile EDS;hEDS;Arthrochalasia Ehlers-Danlos syndrome;Arthrochalasia EDS;aEDS;Dermatosparaxis Ehlers-Danlos syndrome;Dermatosparaxis EDS;dEDS;Kyphoscoliosis Ehlers-Danlos syndrome;Kyphoscoliosis EDS;kEDS;Brittle cornea syndrome;BCS;Spondylodysplastic Ehlers-Danlos Syndrome;spEDS;Musculocontractural Ehlers-Danlos Syndrome;mEDS;D4ST1-deficient Ehlers-Danlos syndrome;Dermatan 4-0-sulfotransferase 1-deficient EDS;D4ST1-deficient EDS;DDEDS;Myopathic Ehlers-Danlos Syndrome;mEDS;Periodontal Ehlers-Danlos Syndrome;pEDS;

Long-term potentiation 💬

[1] PRKCB 💬

Enzastaurin 💬

Enzastaurin

[1] 168 💬

Disease ID

Name

168